Physician profile
Monte E Troutman
NPI 1225000326
$6,193.79
in general payments reported to CMS, 2019-2025
40 companies · $432 in 2025
The $432 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,330 · 2020: $522 · 2021: $927 · 2022: $1,044 · 2023: $1,083 · 2024: $856 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,267 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,267.15 |
| Education | $104.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,477.72 | 2019-2024 | Rinvoq, Skyrizi, Mavyret |
| Janssen Biotech, INC. | $1,215.30 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Actelion Pharmaceuticals US, INC. | $407.08 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Takeda Pharmaceuticals U.S.A., INC. | $300.40 | 2020-2024 | Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $271.05 | 2019-2025 | Xifaxan |
| Boston Scientific Corporation | $270.88 | 2019-2023 | Accolade Sr |
| Steris Corporation | $217.01 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $183.01 | 2021-2023 | Ocaliva |
| Janssen Scientific Affairs, LLC | $180.62 | 2019 | |
| Celltrion USA INC. | $177.58 | 2024 | Zymfentra |
| Shionogi INC | $153.09 | 2019 | |
| Johnson & Johnson Health Care Systems INC. | $139.91 | 2023 | Tremfya |
| Ethicon US, LLC | $118.80 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $101.12 | 2024 | |
| Pfizer INC. | $101.05 | 2023-2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monte Troutman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.